157 related articles for article (PubMed ID: 35530725)
1. Therapeutic approaches and vaccination in fighting COVID-19 infections: A review.
Adibzadeh S; Amiri S; Nia GE; Taleghani MR; Bijarpas ZK; Maserat N; Maali A; Azad M; Behzad-Behbahani A
Gene Rep; 2022 Jun; 27():101619. PubMed ID: 35530725
[TBL] [Abstract][Full Text] [Related]
2. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
Alnefaie A; Albogami S
Saudi Pharm J; 2020 Nov; 28(11):1333-1352. PubMed ID: 32905015
[TBL] [Abstract][Full Text] [Related]
3. Bioactive natural compounds against human coronaviruses: a review and perspective.
Xian Y; Zhang J; Bian Z; Zhou H; Zhang Z; Lin Z; Xu H
Acta Pharm Sin B; 2020 Jul; 10(7):1163-1174. PubMed ID: 32834947
[TBL] [Abstract][Full Text] [Related]
4. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants.
Yin J; Li C; Ye C; Ruan Z; Liang Y; Li Y; Wu J; Luo Z
Comput Struct Biotechnol J; 2022; 20():824-837. PubMed ID: 35126885
[TBL] [Abstract][Full Text] [Related]
5. Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.
Hassanin AA; Haidar Abbas Raza S; Ahmed Ujjan J; Aysh ALrashidi A; Sitohy BM; Al-Surhanee AA; Saad AM; Mohamed Al-Hazani T; Osman Atallah O; Al Syaad KM; Ezzat Ahmed A; Swelum AA; El-Saadony MT; Sitohy MZ
Saudi J Biol Sci; 2022 Apr; 29(4):1981-1997. PubMed ID: 34924802
[TBL] [Abstract][Full Text] [Related]
6. Minireview of progress in the structural study of SARS-CoV-2 proteins.
Zhu G; Zhu C; Zhu Y; Sun F
Curr Res Microb Sci; 2020 Sep; 1():53-61. PubMed ID: 33236001
[TBL] [Abstract][Full Text] [Related]
7. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines.
Hillary VE; Ceasar SA
Heliyon; 2023 Mar; 9(3):e13952. PubMed ID: 36855648
[TBL] [Abstract][Full Text] [Related]
8. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
9. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
10. Insight into the biological impact of COVID-19 and its vaccines on human health.
Ashwlayan VD; Antlash C; Imran M; Asdaq SMB; Alshammari MK; Alomani M; Alzahrani E; Sharma D; Tomar R; Arora MK
Saudi J Biol Sci; 2022 May; 29(5):3326-3337. PubMed ID: 35185356
[TBL] [Abstract][Full Text] [Related]
11. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
[TBL] [Abstract][Full Text] [Related]
12. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
13. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
[TBL] [Abstract][Full Text] [Related]
14. Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.
Zhang ZL; Zhong H; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
Ann Transl Med; 2020 Nov; 8(22):1527. PubMed ID: 33313272
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.
Baig AM; Khaleeq A; Syeda H
J Med Virol; 2020 Nov; 92(11):2792-2803. PubMed ID: 32573788
[TBL] [Abstract][Full Text] [Related]
17. Severe acute respiratory syndrome coronavirus 2 variants-Possibility of universal vaccine design: A review.
Yoon E; Kim D; Jeon H; Kwon Y; Jang Y; Kim S; Hwang KY
Comput Struct Biotechnol J; 2022; 20():3533-3544. PubMed ID: 35765543
[TBL] [Abstract][Full Text] [Related]
18.
Gurung AB
Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
[TBL] [Abstract][Full Text] [Related]
19. COVID-19: A Worldwide, Zoonotic, Pandemic Outbreak.
Khan T; Agnihotri K; Tripathi A; Mukherjee S; Agnihotri N; Gupta G
Altern Ther Health Med; 2020 Aug; 26(S2):56-64. PubMed ID: 32412918
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Zhang C; Zhou C; Shi L; Liu G
Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
